NIH-backed nasal nonaddictive pain prospect clears early test

Feb 15, 2022

admin2022-10-21T08:58:43-04:00February 15th, 2022|Media|

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com